# Subtask Output — Research Graph Neural Networks
## Model: sonar
## Stage: research
## Date: 2026-03-16

## Graph Neural Networks (GNNs) Overview
Graph Neural Networks (GNNs) use **message passing** to aggregate information from neighboring nodes, enabling learning on graph-structured data like molecules or user-item interactions.[1][2] This mechanism captures local and global dependencies through iterative neighbor feature exchanges.

## Message Passing Mechanism
Message passing in GNNs involves nodes exchanging features with neighbors, computed as multi-hop neighbor matrices in models like **ScaleGNN** (arxiv preprint, updated 2026), which fuses low- and high-order features while pruning redundant high-order neighbors via Local Contribution Score (LCS) masking to address over-smoothing.[2]

## Key Models: GCN and GAT
- **Graph Convolutional Networks (GCN)**: Aggregate neighbor features via normalized adjacency matrices; foundational for scalable graph learning, as extended in **ScaleGNN** for web-scale heterogeneous graphs with runtime speedups over baselines like HGAMLP (Liang et al., 2024).[2]
- **Graph Attention Networks (GAT)**: Assign adaptive weights to neighbors using attention mechanisms; integrated in **lncGATSagePre** (published Feb 26, 2026), a two-layer GAT-GraphSAGE model that processes de Bruijn graphs of lncRNA sequences, achieving **weighted F1-score of 0.549** on 4-class subcellular localization (cytoplasm, nucleus, ribosome, exosome), outperforming lncLocator 2.0 and DeepLncLoc.[3]

## Applications in Recommendation Systems
No specific 2026 results found for GNNs/GCN/GAT in recommendation systems despite searches for "graph neural networks recommendation systems 2026 GCN GAT". ScaleGNN supports large heterogeneous graphs relevant to recsys (e.g., user-item), with efficiency gains on real-world datasets via adaptive fusion, but lacks direct recsys benchmarks.[2]

## Applications in Drug Discovery
**GNNs excel in drug discovery** by modeling chemical compounds, proteins, and diseases as knowledge graphs to identify candidates and repurpose drugs via pathway tracing.[1]
- **FragNet**: GNN for molecular property prediction in drug development, predicting properties like solubility for hit identification (JACS, 2015; recent applications noted).[4]
- Contraindication detection: GNNs trace shared protein targets/metabolic paths between drugs.[1]
- Steps for pharma implementation: Standardize entities (e.g., protein names to canonical IDs), build graphs from papers/trials/genomics, continuously update for new trials (2026 medical AI context).[1]
Source: https://www.ayadata.ai/graph-neural-networks-gnns-for-medical-knowledge-representation-in-2026/[1]; https://arxiv.org/html/2504.15920v6[2]; https://pubmed.ncbi.nlm.nih.gov/41762610/[3]; https://pubs.acs.org/doi/10.1021/jacs.5c22620[4]

## Recent Developments (2026)
- **ScaleGNN** (2026): Outperforms SOTA GNNs in accuracy/efficiency on large graphs, reducing runtime via sparsity; suitable for drug graphs.[2] Source: https://arxiv.org/html/2504.15920v6
- **lncGATSagePre** (Feb 26, 2026): GAT+GraphSAGE+SMOTE for lncRNA localization, aiding disease target mining; F1 0.549 on test set.[3] Source: https://pubmed.ncbi.nlm.nih.gov/41762610/
Next steps: Test ScaleGNN on PubChem datasets (10M+ compounds) for drug screening; replicate lncGATSagePre on lncRNA-disease graphs using PyG library (v2.5+).
